Drug Trial Radar · NCT02531490
Early Vascular Adjustments During Hypertensive Pregnancy
Last checked: Nov 20, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
368
Planned (sponsor's estimate)
Start
Jan 1, 2015
Primary completion
Feb 2023
Study completion Apr 2023
Sponsor
- Lead sponsor
- Maastricht University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Paradoxical fetal and maternal results of studies have led to inconsistent use of antihypertensive drugs or no treatment at all in mild to moderate gestational hypertension in the Netherlands. However, none of the studies have taken the individual maternal circulatory state or the contemplated blood pressure response into account. Hypertension may be accompanied by high (hyperdynamic vasodilated profile), normal (normodynamic profile) of low (hypodynamic vasoconstrictive profile) cardiac output, and preeclampsia is not restricted to one circulatory profile. Therefore antihypertensive drugs should be viewed upon as correctors of the hemodynamic state rather than solely reducers of blood pressure. Without taking the maternal hemodynamic profile and condition into account, generic antihypertensive treatment can be expected to result in disappointing, inadequate and paradoxical results. The investigators hypothesize that in mild to moderate hypertension, personalized hemodynamically guided antihypertensive therapy (with target systolic and diastolic blood pressure \<130/80mmHg), prevents the progression to severe hypertension and/or preeclampsia compared to no treatment, without the alleged side-effects.
Conditions
- Hypertension, Pregnancy-Induced
- Pre-Eclampsia
Interventions
LabetalolDrug
NifedipineDrug
MethyldopaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- number of patients with severe gestational hypertensionTime frame: from date of randomization until the date of this study event, assessed up to 1 week post partum (maximum 23weeks after inclusion)
- number of patients with preeclampsiaTime frame: from date of randomization until the date of this study event, assessed up to 1 week post partum (maximum 23weeks after inclusion)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maastricht UMC
Maastricht, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.